NASDAQ:LUNG Pulmonx (LUNG) Stock Price, News & Analysis → Nvidia’s Quiet $1 Trillion Pivot (From Weiss Ratings) (Ad) Free LUNG Stock Alerts $7.06 0.00 (0.00%) (As of 11:04 AM ET) Add Compare Share Share Today's Range$6.95▼$7.0950-Day Range$6.90▼$9.8252-Week Range$6.80▼$14.84Volume19,205 shsAverage Volume488,671 shsMarket Capitalization$274.07 millionP/E RatioN/ADividend YieldN/APrice Target$15.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Pulmonx alerts: Email Address Pulmonx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside122.6% Upside$15.71 Price TargetShort InterestHealthy4.45% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 10 Articles This WeekInsider TradingSelling Shares$98,374 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.15 out of 5 starsMedical Sector454th out of 904 stocksSurgical & Medical Instruments Industry55th out of 97 stocks 3.4 Analyst's Opinion Consensus RatingPulmonx has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePulmonx has only been the subject of 3 research reports in the past 90 days.Read more about Pulmonx's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.45% of the float of Pulmonx has been sold short.Short Interest Ratio / Days to CoverPulmonx has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pulmonx has recently increased by 10.64%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldPulmonx does not currently pay a dividend.Dividend GrowthPulmonx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LUNG. Previous Next 3.1 News and Social Media Coverage News SentimentPulmonx has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Pulmonx this week, compared to 2 articles on an average week.Search Interest6 people have searched for LUNG on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added Pulmonx to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pulmonx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $98,374.00 in company stock.Percentage Held by InsidersOnly 5.70% of the stock of Pulmonx is held by insiders.Percentage Held by Institutions91.04% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pulmonx's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pulmonx are expected to remain at ($1.63) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulmonx is -4.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulmonx is -4.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulmonx has a P/B Ratio of 2.28. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pulmonx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time to watch it.Watch Alex's "Next Magnificent Seven" presentation now. About Pulmonx Stock (NASDAQ:LUNG)Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Read More LUNG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LUNG Stock News HeadlinesJune 6 at 7:54 AM | insidertrades.comPulmonx Co. (NASDAQ:LUNG) Insider Geoffrey Beran Rose Sells 4,297 SharesJune 6 at 7:54 AM | insidertrades.comInsider Selling: Pulmonx Co. (NASDAQ:LUNG) General Counsel Sells 5,475 Shares of StockMay 24, 2024 | insidertrades.comPulmonx Co. (NASDAQ:LUNG) Insider Sells $10,312.64 in StockJune 6 at 7:56 AM | americanbankingnews.comPulmonx Co. (NASDAQ:LUNG) General Counsel David Aaron Lehman Sells 5,475 SharesJune 5 at 3:56 AM | americanbankingnews.comPulmonx (NASDAQ:LUNG) Now Covered by Analysts at Lake Street CapitalJune 1, 2024 | americanbankingnews.comPulmonx Co. (NASDAQ:LUNG) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 6, 2024 | globenewswire.comPulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 4, 2024 | finance.yahoo.comEarnings Update: Pulmonx Corporation (NASDAQ:LUNG) Just Reported Its First-Quarter Results And Analysts Are Updating Their ForecastsMay 3, 2024 | finance.yahoo.comPulmonx First Quarter 2024 Earnings: Beats ExpectationsMay 3, 2024 | finance.yahoo.comPulmonx Corporation (NASDAQ:LUNG) Q1 2024 Earnings Call TranscriptMay 2, 2024 | markets.businessinsider.comAnalyst Recommendation Report Summary: Insights and Strategic Investment PerspectivesMay 2, 2024 | marketwatch.comPulmonx Surge After Strong 1Q PerformanceMay 2, 2024 | finance.yahoo.comQ1 2024 Pulmonx Corp Earnings CallMay 2, 2024 | finance.yahoo.comPulmonx Corp (LUNG) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and Improved ...May 1, 2024 | investorplace.comLUNG Stock Earnings: Pulmonx Beats EPS, Beats Revenue for Q1 2024May 1, 2024 | finance.yahoo.comPulmonx Corp (LUNG) Q1 2024 Earnings: Surpasses Revenue Estimates Amidst Continued LossesMay 1, 2024 | globenewswire.comPulmonx Reports First Quarter 2024 Financial ResultsApril 25, 2024 | finance.yahoo.comPulmonx Corporation (LUNG) Stock Price, News, Quote & History - Yahoo FinanceApril 10, 2024 | globenewswire.comPulmonx to Report First Quarter 2024 Financial Results on May 1, 2024April 4, 2024 | investing.comPulmonx names new CFO to bolster financial leadershipApril 3, 2024 | markets.businessinsider.comNavigating 6 Analyst Ratings For PulmonxApril 2, 2024 | marketwatch.comPulmonx Taps Mehul Joshi as Finance ChiefApril 2, 2024 | globenewswire.comPulmonx Announces Appointment of Mehul Joshi as Chief Financial OfficerMarch 17, 2024 | ca.finance.yahoo.comLUNG Apr 2024 12.500 callMarch 16, 2024 | finanznachrichten.dePulmonx Corporation: Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive LUNG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today6/06/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:LUNG CUSIPN/A CIK1127537 Webpulmonx.com Phone1-650-364-0400FaxN/AEmployees279Year FoundedN/APrice Target and Rating Average Stock Price Target$15.71 High Stock Price Target$18.00 Low Stock Price Target$12.00 Potential Upside/Downside+122.6%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,840,000.00 Net Margins-80.46% Pretax Margin-79.59% Return on Equity-48.09% Return on Assets-32.61% Debt Debt-to-Equity Ratio0.29 Current Ratio6.95 Quick Ratio6.14 Sales & Book Value Annual Sales$68.68 million Price / Sales3.99 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book2.28Miscellaneous Outstanding Shares38,820,000Free Float36,603,000Market Cap$274.07 million OptionableOptionable Beta0.64 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. David A. Lehman (Age 63)General Counsel & Secretary Comp: $651.39kMr. Geoffrey Beran Rose (Age 50)Chief Commercial Officer Comp: $632.29kMr. Steven S. Williamson (Age 51)CEO, President & Director Mr. Mehul Joshi (Age 63)Chief Financial Officer Mr. Sri RadhakrishnanChief Technical OfficerMs. Marcee M. Maroney (Age 54)Vice President of Marketing Sarah HuberVice President of Sales (U.S.)Ms. Lisa Paul (Age 60)Chief People Officer Mr. Jérôme ErathSenior VP & GM of Europe Middle-East & AfricaMr. John B. McKune (Age 48)VP & Corporate Controller More ExecutivesKey CompetitorsCardiovascular SystemsNASDAQ:CSIIMiMedx GroupNASDAQ:MDXGAtriCureNASDAQ:ATRCArtivionNYSE:AORTPerspective TherapeuticsNYSE:CATXView All CompetitorsInsiders & InstitutionsGeoffrey Beran RoseSold 4,297 sharesTotal: $29,950.09 ($6.97/share)David Aaron LehmanSold 5,475 sharesTotal: $38,160.75 ($6.97/share)Geoffrey Beran RoseSold 1,184 sharesTotal: $10,312.64 ($8.71/share)Jacobs Levy Equity Management Inc.Sold 167,457 shares on 5/16/2024Ownership: 0.508%California State Teachers Retirement SystemSold 1,780 shares on 5/16/2024Ownership: 0.089%View All Insider TransactionsView All Institutional Transactions LUNG Stock Analysis - Frequently Asked Questions Should I buy or sell Pulmonx stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pulmonx in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LUNG shares. View LUNG analyst ratings or view top-rated stocks. What is Pulmonx's stock price target for 2024? 7 Wall Street research analysts have issued twelve-month target prices for Pulmonx's shares. Their LUNG share price targets range from $12.00 to $18.00. On average, they predict the company's share price to reach $15.71 in the next twelve months. This suggests a possible upside of 122.6% from the stock's current price. View analysts price targets for LUNG or view top-rated stocks among Wall Street analysts. How have LUNG shares performed in 2024? Pulmonx's stock was trading at $12.75 at the beginning of 2024. Since then, LUNG stock has decreased by 44.6% and is now trading at $7.06. View the best growth stocks for 2024 here. When is Pulmonx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our LUNG earnings forecast. How were Pulmonx's earnings last quarter? Pulmonx Co. (NASDAQ:LUNG) announced its quarterly earnings data on Wednesday, May, 1st. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.07. The business earned $18.85 million during the quarter, compared to analysts' expectations of $17.54 million. Pulmonx had a negative trailing twelve-month return on equity of 48.09% and a negative net margin of 80.46%. During the same period in the prior year, the firm posted ($0.42) earnings per share. What guidance has Pulmonx issued on next quarter's earnings? Pulmonx issued an update on its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $81.0 million-$84.0 million, compared to the consensus revenue estimate of $82.2 million. When did Pulmonx IPO? Pulmonx (LUNG) raised $100 million in an initial public offering (IPO) on Thursday, October 1st 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers. Who are Pulmonx's major shareholders? Pulmonx's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.39%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (2.57%), Jacobs Levy Equity Management Inc. (0.51%), Sei Investments Co. (0.19%), Price T Rowe Associates Inc. MD (0.09%) and Russell Investments Group Ltd. (0.09%). Insiders that own company stock include Alissa Hsu Lynch, Daniel P Florin, David Aaron Lehman, Derrick Sung, Geoffrey Beran Rose, Glendon E French III, John Mckune, Richard Ferrari and Scientific Corp Boston. View institutional ownership trends. How do I buy shares of Pulmonx? Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LUNG) was last updated on 6/6/2024 by MarketBeat.com Staff From Our PartnersBitcoin’s Biggest Year Yet2024 is set to be a historic year for Bitcoin. It’s all thanks to three major catalysts that I reveal in my...Paradigm Press | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredEverything from semiconductors to space shuttles depend on this overlooked mineralBoron is also at the heart of a breakthrough that could fuel one of mankind's most sensational advances in sem...Capital Trends | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC | SponsoredBill Clinton Backing Biden Replacement???Bill Clinton is back. And he just met in Mexico with the one person I believe could REPLACE Joe Biden by Au...The Freeport Society | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an eff...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmonx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmonx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
